What is on the horizon for the management of osteosarcoma?
2021 ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guidelines open the door to genetic testing but the search for new treatments continues
Single-agent doxorubicin – is it still the standard first-line therapy for all soft tissue sarcoma subtypes?
In practice, doxorubicin alone is often not used as the first-line standard of care for soft tissue sarcomas; however, a lack of high-quality survival data precludes other regimens becoming the gold standard
Optimising clinical trials for greater inclusiveness
Oncologists are aiming to capitalise on lessons learned from the COVID-19 pandemic and design more inclusive clinical trials, optimise trial endpoints and make better use of real-world evidence.
Bringing a child into a family’s battle with cancer
Available data now allows evidence-based treatment of cancer diagnosed during pregnancy and new therapies are improving many young patients’ survival prospects, but couples’ preferences and values must continue to guide medical teams even when hope is scarce
Genetics and availability of treatments influence the management of head and neck cancer in Asia
The Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines is presented at the ESMO Asia Virtual Oncology Week 2021
Should renal cell carcinomas be managed differently in Asia?
The Pan-Asian adaptation of the ESMO guidelines introduces some changes to the standard of care in Europe, including diagnostic tests and the use of cytoreductive nephrectomy
Some practice-changing results in breast cancer are perceived differently in low-resourced countries
Cost, limited drug availability and lack of diagnostic testing facilities are hurdles to adopting practice-changing recommendations in some Asian countries
How can quantifying the burden of rare cancers in Asia improve patient outcomes?
National cancer control programmes, pharmaceutical company interest and facilitation of clinical trial participation may be stimulated by epidemiological data
Cancer is an independent risk factor for COVID-19 mortality in hospitalised patients
Findings from international registries improve knowledge on how to manage cancer care in the pandemic era
Efficacy of COVID-19 vaccine in cancer patients is comparable to levels reported in the general population
Initial delays to antibody production are followed by similar levels of vaccine efficacy after a second vaccine dose